Revance agrees to lower-priced buyout offer by Crown Laboratories

Revance Therapeutics

09/12/2024 13:42

Dec 9 (Reuters) - Anti-wrinkle injection maker Revance
Therapeutics  RVNC.O  has agreed to be bought for $3.10 per
share by privately held Crown Laboratories, instead of $6.66 per
share agreed previously, the two companies said on Monday.
    Shares of Revance were down 20.4% in premarket trade.

 (Reporting by Puyaan Singh in Bengaluru; Editing by Vijay
Kishore)
 ((Puyaan.Singh@thomsonreuters.com;))